Xeltis key facts
as of Oct 2026- Developer of medical devices designed to provide a restorative approach to cardiovascular therapy.
- Xeltis is valued at approximately $107.5M as of Oct 2026 (last reported valuation).
- It has raised $268.6M; the latest was Later Stage VC ($57.8M) in Dec 2025.
- Notable investors include European Innovation Council, Invest-NL (Investment Company), EQT Life Sciences, Kurma Partners, Vi Partners — 14 tracked in total.
- Status: Privately Held (backing).
Xeltis's last reported valuation, Jun 2023. Nothing priced has surfaced since.
- ·The complete investor list: 14 names
- ·Watch Xeltis: the Monday email on marks, rounds and moves
Xeltis funding rounds
No funding rounds for Xeltis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Xeltis
14+Xeltis valuation
Xeltis's last reported valuation was $107 million in Jun 2023. No priced round, secondary trade or fund mark has surfaced since.
Xeltis investors
14 investors are on record for Xeltis, including European Innovation Council, Invest-NL (Investment Company), EQT Life Sciences and Kurma Partners. By type, the record holds 4 venture capital firms and 1 family office.
About Xeltis
Developer of medical devices designed to provide a restorative approach to cardiovascular therapy. The company's device comprises bioresorbable implants that facilitate bioabsorbable heart valves and blood vessels to stimulate the body to create its natural vessel tissue, enabling doctors to help patients improve their requiring vascular interventions.
- Sector
- Healthcare
- HQ
- Eindhoven, Netherlands
- Founded
- 2006
- Employees
- 56
- Website
- xeltis.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.